ID   MK07_HUMAN              Reviewed;         816 AA.
AC   Q13164; Q16634; Q59F50; Q6QLU7; Q7L4P4; Q969G1; Q96G51;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   02-SEP-2008, sequence version 2.
DT   12-OCT-2022, entry version 208.
DE   RecName: Full=Mitogen-activated protein kinase 7;
DE            Short=MAP kinase 7;
DE            Short=MAPK 7;
DE            EC=2.7.11.24;
DE   AltName: Full=Big MAP kinase 1;
DE            Short=BMK-1;
DE   AltName: Full=Extracellular signal-regulated kinase 5;
DE            Short=ERK-5;
GN   Name=MAPK7; Synonyms=BMK1, ERK5, PRKM7;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA].
RC   TISSUE=Placenta;
RX   PubMed=7646528; DOI=10.1006/bbrc.1995.2189;
RA   Lee J.-D., Ulevitch R.J., Han J.;
RT   "Primary structure of BMK1: a new mammalian map kinase.";
RL   Biochem. Biophys. Res. Commun. 213:715-724(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], INTERACTION WITH MAP2K5, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Fetal brain;
RX   PubMed=7759517; DOI=10.1074/jbc.270.21.12665;
RA   Zhou G., Bao Z.Q., Dixon J.E.;
RT   "Components of a new human protein kinase signal transduction pathway.";
RL   J. Biol. Chem. 270:12665-12669(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RC   TISSUE=Placenta;
RX   PubMed=15716121; DOI=10.1016/j.gene.2004.11.011;
RA   McCaw B.J., Chow S.Y., Wong E.S.M., Tan K.L., Guo H., Guy G.R.;
RT   "Identification and characterization of mErk5-T, a novel Erk5/Bmk1 splice
RT   variant.";
RL   Gene 345:183-190(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   TISSUE=Spleen;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Muscle, and Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PROTEIN SEQUENCE OF 2-35; 75-98; 119-131; 198-205; 296-343; 377-392;
RP   468-485; 489-505; 544-571; 720-735 AND 798-816, CLEAVAGE OF INITIATOR
RP   METHIONINE, ACETYLATION AT ALA-2, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Hepatoma;
RA   Bienvenut W.V., Fleming J., Leug H.Y.;
RL   Submitted (JAN-2010) to UniProtKB.
RN   [8]
RP   FUNCTION, ACTIVITY REGULATION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   219-THR--TYR-221.
RX   PubMed=9384584; DOI=10.1093/emboj/16.23.7054;
RA   Kato Y., Kravchenko V.V., Tapping R.I., Han J., Ulevitch R.J., Lee J.-D.;
RT   "BMK1/ERK5 regulates serum-induced early gene expression through
RT   transcription factor MEF2C.";
RL   EMBO J. 16:7054-7066(1997).
RN   [9]
RP   FUNCTION, AND ACTIVITY REGULATION.
RX   PubMed=9790194; DOI=10.1038/27234;
RA   Kato Y., Tapping R.I., Huang S., Watson M.H., Ulevitch R.J., Lee J.-D.;
RT   "Bmk1/Erk5 is required for cell proliferation induced by epidermal growth
RT   factor.";
RL   Nature 395:713-716(1998).
RN   [10]
RP   FUNCTION, AND INTERACTION WITH SGK1.
RX   PubMed=11254654; DOI=10.1074/jbc.c000838200;
RA   Hayashi M., Tapping R.I., Chao T.H., Lo J.F., King C.C., Yang Y., Lee J.D.;
RT   "BMK1 mediates growth factor-induced cell proliferation through direct
RT   cellular activation of serum and glucocorticoid-inducible kinase.";
RL   J. Biol. Chem. 276:8631-8634(2001).
RN   [11]
RP   FUNCTION.
RX   PubMed=11278431; DOI=10.1074/jbc.m008748200;
RA   Dong F., Gutkind J.S., Larner A.C.;
RT   "Granulocyte colony-stimulating factor induces ERK5 activation, which is
RT   differentially regulated by protein-tyrosine kinases and protein kinase C.
RT   Regulation of cell proliferation and survival.";
RL   J. Biol. Chem. 276:10811-10816(2001).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-720 AND THR-733, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [14]
RP   INTERACTION WITH HSP90AB1.
RX   PubMed=23428871; DOI=10.1128/mcb.01246-12;
RA   Erazo T., Moreno A., Ruiz-Babot G., Rodriguez-Asiain A., Morrice N.A.,
RA   Espadamala J., Bayascas J.R., Gomez N., Lizcano J.M.;
RT   "Canonical and kinase activity-independent mechanisms for extracellular
RT   signal-regulated kinase 5 (ERK5) nuclear translocation require dissociation
RT   of Hsp90 from the ERK5-Cdc37 complex.";
RL   Mol. Cell. Biol. 33:1671-1686(2013).
RN   [15]
RP   FUNCTION, SUBCELLULAR LOCATION, PHOSPHORYLATION, AND INTERACTION WITH PML.
RX   PubMed=22869143; DOI=10.1038/onc.2012.332;
RA   Yang Q., Liao L., Deng X., Chen R., Gray N.S., Yates J.R. III, Lee J.D.;
RT   "BMK1 is involved in the regulation of p53 through disrupting the PML-MDM2
RT   interaction.";
RL   Oncogene 32:3156-3164(2013).
RN   [16]
RP   VARIANTS [LARGE SCALE ANALYSIS] HIS-535 AND ALA-550.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Plays a role in various cellular processes such as
CC       proliferation, differentiation and cell survival. The upstream
CC       activator of MAPK7 is the MAPK kinase MAP2K5. Upon activation, it
CC       translocates to the nucleus and phosphorylates various downstream
CC       targets including MEF2C. EGF activates MAPK7 through a Ras-independent
CC       and MAP2K5-dependent pathway. May have a role in muscle cell
CC       differentiation. May be important for endothelial function and
CC       maintenance of blood vessel integrity. MAP2K5 and MAPK7 interact
CC       specifically with one another and not with MEK1/ERK1 or MEK2/ERK2
CC       pathways. Phosphorylates SGK1 at Ser-78 and this is required for growth
CC       factor-induced cell cycle progression. Involved in the regulation of
CC       p53/TP53 by disrupting the PML-MDM2 interaction.
CC       {ECO:0000269|PubMed:11254654, ECO:0000269|PubMed:11278431,
CC       ECO:0000269|PubMed:22869143, ECO:0000269|PubMed:9384584,
CC       ECO:0000269|PubMed:9790194}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.24;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.24;
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC   -!- ACTIVITY REGULATION: Activated by tyrosine and threonine
CC       phosphorylation (By similarity). Activated in response to
CC       hyperosmolarity, hydrogen peroxide, and epidermal growth factor (EGF).
CC       {ECO:0000250, ECO:0000269|PubMed:9384584, ECO:0000269|PubMed:9790194}.
CC   -!- SUBUNIT: Interacts with MAP2K5. Forms oligomers (By similarity).
CC       Interacts with MEF2A, MEF2C and MEF2D; the interaction phosphorylates
CC       the MEF2s and enhances transcriptional activity of MEF2A, MEF2C but not
CC       MEF2D (By similarity). Interacts with SGK1. Preferentially interacts
CC       with PML isoform PML-4 but shows interaction also with its other
CC       isoforms: isoform PML-1, isoform PML-2, isoform PML-3 and isoform PML-
CC       6. Interacts (via N-terminal half) with HSP90AB1-CDC37 chaperone
CC       complex in resting cells; the interaction is MAP2K5-independent and
CC       prevents MAPK7 from ubiquitination and proteasomal degradation
CC       (PubMed:23428871). {ECO:0000250, ECO:0000269|PubMed:11254654,
CC       ECO:0000269|PubMed:22869143, ECO:0000269|PubMed:23428871,
CC       ECO:0000269|PubMed:7759517}.
CC   -!- INTERACTION:
CC       Q13164; O95816: BAG2; NbExp=3; IntAct=EBI-1213983, EBI-355275;
CC       Q13164; Q16204: CCDC6; NbExp=3; IntAct=EBI-1213983, EBI-1045350;
CC       Q13164; Q13163: MAP2K5; NbExp=7; IntAct=EBI-1213983, EBI-307294;
CC       Q13164; Q02078-6: MEF2A; NbExp=3; IntAct=EBI-1213983, EBI-16437973;
CC       Q13164; P29590: PML; NbExp=6; IntAct=EBI-1213983, EBI-295890;
CC       Q13164; O00762: UBE2C; NbExp=3; IntAct=EBI-1213983, EBI-719691;
CC       Q13164; Q5TZN3: UBE2C; NbExp=3; IntAct=EBI-1213983, EBI-10247554;
CC       Q13164; P17029: ZKSCAN1; NbExp=3; IntAct=EBI-1213983, EBI-10199654;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Nucleus, PML body.
CC       Note=Translocates to the nucleus upon activation.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=Q13164-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q13164-2; Sequence=VSP_035198;
CC       Name=3;
CC         IsoId=Q13164-3; Sequence=VSP_035200;
CC       Name=4;
CC         IsoId=Q13164-4; Sequence=VSP_035199, VSP_035200;
CC   -!- TISSUE SPECIFICITY: Expressed in many adult tissues. Abundant in heart,
CC       placenta, lung, kidney and skeletal muscle. Not detectable in liver.
CC       {ECO:0000269|PubMed:7759517}.
CC   -!- DOMAIN: The second proline-rich region may interact with actin
CC       targeting the kinase to a specific location in the cell.
CC   -!- DOMAIN: The TXY motif contains the threonine and tyrosine residues
CC       whose phosphorylation activates the MAP kinases.
CC   -!- PTM: Dually phosphorylated on Thr-219 and Tyr-221, which activates the
CC       enzyme (By similarity). Autophosphorylated in vitro on threonine and
CC       tyrosine residues when the C-terminal part of the kinase, which could
CC       have a regulatory role, is absent. {ECO:0000250,
CC       ECO:0000269|PubMed:22869143}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC Ser/Thr
CC       protein kinase family. MAP kinase subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA81381.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=BAD92848.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/MAPK7ID41294ch17p11.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U29725; AAA82931.1; -; mRNA.
DR   EMBL; U29726; AAA82932.1; -; mRNA.
DR   EMBL; U29727; AAA82933.1; -; Genomic_DNA.
DR   EMBL; U25278; AAA81381.1; ALT_FRAME; mRNA.
DR   EMBL; AY534741; AAS38577.1; -; mRNA.
DR   EMBL; AB209611; BAD92848.1; ALT_INIT; mRNA.
DR   EMBL; CH471212; EAW50883.1; -; Genomic_DNA.
DR   EMBL; CH471212; EAW50886.1; -; Genomic_DNA.
DR   EMBL; BC007404; AAH07404.1; -; mRNA.
DR   EMBL; BC007992; AAH07992.1; -; mRNA.
DR   EMBL; BC009963; AAH09963.1; -; mRNA.
DR   EMBL; BC030134; AAH30134.1; -; mRNA.
DR   CCDS; CCDS11206.1; -. [Q13164-1]
DR   CCDS; CCDS11207.1; -. [Q13164-2]
DR   PIR; B56708; B56708.
DR   RefSeq; NP_002740.2; NM_002749.3. [Q13164-1]
DR   RefSeq; NP_620601.1; NM_139032.2. [Q13164-2]
DR   RefSeq; NP_620602.2; NM_139033.2. [Q13164-1]
DR   RefSeq; NP_620603.2; NM_139034.2. [Q13164-1]
DR   RefSeq; XP_011522259.1; XM_011523957.2. [Q13164-2]
DR   PDB; 2Q8Y; X-ray; 2.00 A; B=215-223.
DR   PDB; 4B99; X-ray; 2.80 A; A=1-397.
DR   PDB; 4IC7; X-ray; 2.60 A; A/D=1-431.
DR   PDB; 4IC8; X-ray; 2.80 A; A/B=1-431.
DR   PDB; 4ZSG; X-ray; 1.79 A; A=47-393.
DR   PDB; 4ZSJ; X-ray; 2.48 A; A=50-393.
DR   PDB; 4ZSL; X-ray; 2.25 A; A=53-393.
DR   PDB; 5BYY; X-ray; 2.79 A; A=49-394.
DR   PDB; 5BYZ; X-ray; 1.65 A; A=48-395.
DR   PDB; 5O7I; X-ray; 2.38 A; A=46-402.
DR   PDB; 6HKM; X-ray; 2.47 A; A=49-395.
DR   PDB; 6HKN; X-ray; 2.33 A; A=54-393.
DR   PDBsum; 2Q8Y; -.
DR   PDBsum; 4B99; -.
DR   PDBsum; 4IC7; -.
DR   PDBsum; 4IC8; -.
DR   PDBsum; 4ZSG; -.
DR   PDBsum; 4ZSJ; -.
DR   PDBsum; 4ZSL; -.
DR   PDBsum; 5BYY; -.
DR   PDBsum; 5BYZ; -.
DR   PDBsum; 5O7I; -.
DR   PDBsum; 6HKM; -.
DR   PDBsum; 6HKN; -.
DR   AlphaFoldDB; Q13164; -.
DR   SMR; Q13164; -.
DR   BioGRID; 111584; 136.
DR   IntAct; Q13164; 108.
DR   MINT; Q13164; -.
DR   STRING; 9606.ENSP00000311005; -.
DR   BindingDB; Q13164; -.
DR   ChEMBL; CHEMBL5332; -.
DR   DrugBank; DB00945; Acetylsalicylic acid.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB01017; Minocycline.
DR   DrugCentral; Q13164; -.
DR   GuidetoPHARMACOLOGY; 2093; -.
DR   GlyGen; Q13164; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q13164; -.
DR   PhosphoSitePlus; Q13164; -.
DR   BioMuta; MAPK7; -.
DR   DMDM; 205371766; -.
DR   CPTAC; CPTAC-887; -.
DR   CPTAC; CPTAC-888; -.
DR   EPD; Q13164; -.
DR   jPOST; Q13164; -.
DR   MassIVE; Q13164; -.
DR   MaxQB; Q13164; -.
DR   PaxDb; Q13164; -.
DR   PeptideAtlas; Q13164; -.
DR   PRIDE; Q13164; -.
DR   ProteomicsDB; 59203; -. [Q13164-1]
DR   ProteomicsDB; 59204; -. [Q13164-2]
DR   ProteomicsDB; 59205; -. [Q13164-3]
DR   ProteomicsDB; 59206; -. [Q13164-4]
DR   Antibodypedia; 4345; 678 antibodies from 40 providers.
DR   DNASU; 5598; -.
DR   Ensembl; ENST00000299612.11; ENSP00000299612.7; ENSG00000166484.20. [Q13164-2]
DR   Ensembl; ENST00000308406.9; ENSP00000311005.5; ENSG00000166484.20. [Q13164-1]
DR   Ensembl; ENST00000395602.8; ENSP00000378966.4; ENSG00000166484.20. [Q13164-1]
DR   Ensembl; ENST00000395604.8; ENSP00000378968.3; ENSG00000166484.20. [Q13164-1]
DR   GeneID; 5598; -.
DR   KEGG; hsa:5598; -.
DR   MANE-Select; ENST00000395604.8; ENSP00000378968.3; NM_002749.4; NP_002740.2.
DR   UCSC; uc002gvn.4; human. [Q13164-1]
DR   CTD; 5598; -.
DR   DisGeNET; 5598; -.
DR   GeneCards; MAPK7; -.
DR   HGNC; HGNC:6880; MAPK7.
DR   HPA; ENSG00000166484; Low tissue specificity.
DR   MalaCards; MAPK7; -.
DR   MIM; 602521; gene.
DR   neXtProt; NX_Q13164; -.
DR   OpenTargets; ENSG00000166484; -.
DR   PharmGKB; PA30625; -.
DR   VEuPathDB; HostDB:ENSG00000166484; -.
DR   eggNOG; KOG0660; Eukaryota.
DR   GeneTree; ENSGT00940000160215; -.
DR   HOGENOM; CLU_008789_1_0_1; -.
DR   InParanoid; Q13164; -.
DR   OMA; NWSGQQL; -.
DR   OrthoDB; 741207at2759; -.
DR   PhylomeDB; Q13164; -.
DR   TreeFam; TF105099; -.
DR   BRENDA; 2.7.11.24; 2681.
DR   PathwayCommons; Q13164; -.
DR   Reactome; R-HSA-198753; ERK/MAPK targets.
DR   Reactome; R-HSA-198765; Signalling to ERK5.
DR   Reactome; R-HSA-202670; ERKs are inactivated.
DR   Reactome; R-HSA-2559582; Senescence-Associated Secretory Phenotype (SASP).
DR   Reactome; R-HSA-881907; Gastrin-CREB signalling pathway via PKC and MAPK.
DR   Reactome; R-HSA-8853659; RET signaling.
DR   SignaLink; Q13164; -.
DR   SIGNOR; Q13164; -.
DR   BioGRID-ORCS; 5598; 16 hits in 1115 CRISPR screens.
DR   ChiTaRS; MAPK7; human.
DR   GeneWiki; MAPK7; -.
DR   GenomeRNAi; 5598; -.
DR   Pharos; Q13164; Tchem.
DR   PRO; PR:Q13164; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; Q13164; protein.
DR   Bgee; ENSG00000166484; Expressed in lower esophagus mucosa and 137 other tissues.
DR   ExpressionAtlas; Q13164; baseline and differential.
DR   Genevisible; Q13164; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:BHF-UCL.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0016605; C:PML body; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004707; F:MAP kinase activity; IBA:GO_Central.
DR   GO; GO:0051019; F:mitogen-activated protein kinase binding; IPI:BHF-UCL.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0033173; P:calcineurin-NFAT signaling cascade; IEA:Ensembl.
DR   GO; GO:0019933; P:cAMP-mediated signaling; NAS:BHF-UCL.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0030154; P:cell differentiation; IEA:UniProtKB-KW.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; IGI:BHF-UCL.
DR   GO; GO:0070301; P:cellular response to hydrogen peroxide; IMP:BHF-UCL.
DR   GO; GO:0071499; P:cellular response to laminar fluid shear stress; IMP:BHF-UCL.
DR   GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IDA:UniProtKB.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0070885; P:negative regulation of calcineurin-NFAT signaling cascade; IEA:Ensembl.
DR   GO; GO:0051344; P:negative regulation of cyclic-nucleotide phosphodiesterase activity; NAS:BHF-UCL.
DR   GO; GO:2000352; P:negative regulation of endothelial cell apoptotic process; IMP:BHF-UCL.
DR   GO; GO:2001240; P:negative regulation of extrinsic apoptotic signaling pathway in absence of ligand; IGI:BHF-UCL.
DR   GO; GO:0034115; P:negative regulation of heterotypic cell-cell adhesion; IGI:BHF-UCL.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; TAS:BHF-UCL.
DR   GO; GO:1902176; P:negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0060761; P:negative regulation of response to cytokine stimulus; IGI:BHF-UCL.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IEA:Ensembl.
DR   GO; GO:0051247; P:positive regulation of protein metabolic process; IGI:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IGI:BHF-UCL.
DR   GO; GO:0036003; P:positive regulation of transcription from RNA polymerase II promoter in response to stress; IMP:BHF-UCL.
DR   GO; GO:0045765; P:regulation of angiogenesis; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   DisProt; DP02831; -.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR003527; MAP_kinase_CS.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS01351; MAPK; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ATP-binding; Cell cycle;
KW   Cytoplasm; Differentiation; Direct protein sequencing; Kinase;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000269|Ref.7"
FT   CHAIN           2..816
FT                   /note="Mitogen-activated protein kinase 7"
FT                   /id="PRO_0000186260"
FT   DOMAIN          55..347
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1..26
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2..77
FT                   /note="Required for cytoplasmic targeting"
FT                   /evidence="ECO:0000250"
FT   REGION          78..139
FT                   /note="Required for binding to MAP2K5"
FT                   /evidence="ECO:0000250"
FT   REGION          140..406
FT                   /note="Necessary for oligomerization"
FT                   /evidence="ECO:0000250"
FT   REGION          406..737
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          407..806
FT                   /note="May not be required for kinase activity; required to
FT                   stimulate MEF2C activity"
FT                   /evidence="ECO:0000250"
FT   MOTIF           219..221
FT                   /note="TXY"
FT   MOTIF           505..539
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000250"
FT   COMPBIAS        1..15
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        429..464
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        506..545
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        584..614
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        628..655
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        674..696
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        700..722
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        182
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         61..69
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         84
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0000269|Ref.7"
FT   MOD_RES         720
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         733
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   VAR_SEQ         1..139
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_035198"
FT   VAR_SEQ         1..133
FT                   /note="MAEPLKEEDGEDGSAEPPGPVKAEPAHTAASVAAKNLALLKARSFDVTFDVG
FT                   DEYEIIETIGNGAYGVVSSARRRLTGQQVAIKKIPNAFDVVTNAKRTLRELKILKHFKH
FT                   DNIIAIKDILRPTVPYGEFKSV -> MLFFHTMPSAPMGSQGKAVTCLESEGCGEDGAC
FT                   PWSVIRPTHASLLPSPSS (in isoform 4)"
FT                   /evidence="ECO:0000303|Ref.4"
FT                   /id="VSP_035199"
FT   VAR_SEQ         493..816
FT                   /note="DGPSAPLEAPEPRKPVTAQERQREREEKRRRRQERAKEREKRRQERERKERG
FT                   AGASGGPSTDPLAGLVLSDNDRSLLERWTRMARPAAPALTSVPAPAPAPTPTPTPVQPT
FT                   SPPPGPVAQPTGPQPQSAGSTSGPVPQPACPPPGPAPHPTGPPGPIPVPAPPQIATSTS
FT                   LLAAQSLVPPPGLPGSSTPGVLPYFPPGLPPPDAGGAPQSSMSESPDVNLVTQQLSKSQ
FT                   VEDPLPPVFSGTPKGSGAGYGVGFDLEEFLNQSFDMGVADGPQDGQADSASLSASLLAD
FT                   WLEGHGMNPADIESLQREIQMDSPMLLADLPDLQDP -> GALWAGRVGRGETWTWTRL
FT                   QAFTFSPAQLPRKWPQRTPGGS (in isoform 3 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:15716121, ECO:0000303|Ref.4"
FT                   /id="VSP_035200"
FT   VARIANT         535
FT                   /note="R -> H"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_046225"
FT   VARIANT         550
FT                   /note="G -> A (in dbSNP:rs56388327)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042257"
FT   MUTAGEN         219..221
FT                   /note="TEY->AEF: Loss activation by MAP2K5."
FT                   /evidence="ECO:0000269|PubMed:9384584"
FT   CONFLICT        610
FT                   /note="V -> L (in Ref. 1; AAA81381)"
FT                   /evidence="ECO:0000305"
FT   TURN            45..48
FT                   /evidence="ECO:0007829|PDB:4IC8"
FT   STRAND          53..64
FT                   /evidence="ECO:0007829|PDB:5BYZ"
FT   STRAND          67..74
FT                   /evidence="ECO:0007829|PDB:5BYZ"
FT   TURN            75..77
FT                   /evidence="ECO:0007829|PDB:5BYZ"
FT   STRAND          80..86
FT                   /evidence="ECO:0007829|PDB:5BYZ"
FT   TURN            87..90
FT                   /evidence="ECO:0007829|PDB:5BYZ"
FT   HELIX           93..108
FT                   /evidence="ECO:0007829|PDB:5BYZ"
FT   STRAND          117..120
FT                   /evidence="ECO:0007829|PDB:5BYZ"
FT   HELIX           127..129
FT                   /evidence="ECO:0007829|PDB:5BYZ"
FT   STRAND          133..137
FT                   /evidence="ECO:0007829|PDB:5BYZ"
FT   STRAND          141..143
FT                   /evidence="ECO:0007829|PDB:6HKN"
FT   HELIX           144..148
FT                   /evidence="ECO:0007829|PDB:5BYZ"
FT   STRAND          150..152
FT                   /evidence="ECO:0007829|PDB:5BYZ"
FT   HELIX           156..175
FT                   /evidence="ECO:0007829|PDB:5BYZ"
FT   HELIX           185..187
FT                   /evidence="ECO:0007829|PDB:5BYZ"
FT   STRAND          188..190
FT                   /evidence="ECO:0007829|PDB:5BYZ"
FT   STRAND          196..198
FT                   /evidence="ECO:0007829|PDB:5BYZ"
FT   HELIX           201..203
FT                   /evidence="ECO:0007829|PDB:6HKN"
FT   HELIX           214..216
FT                   /evidence="ECO:0007829|PDB:5BYZ"
FT   HELIX           219..221
FT                   /evidence="ECO:0007829|PDB:5BYZ"
FT   HELIX           225..227
FT                   /evidence="ECO:0007829|PDB:5BYZ"
FT   HELIX           230..234
FT                   /evidence="ECO:0007829|PDB:5BYZ"
FT   HELIX           242..257
FT                   /evidence="ECO:0007829|PDB:5BYZ"
FT   HELIX           267..278
FT                   /evidence="ECO:0007829|PDB:5BYZ"
FT   HELIX           283..287
FT                   /evidence="ECO:0007829|PDB:5BYZ"
FT   STRAND          288..290
FT                   /evidence="ECO:0007829|PDB:4IC8"
FT   HELIX           292..300
FT                   /evidence="ECO:0007829|PDB:5BYZ"
FT   HELIX           309..312
FT                   /evidence="ECO:0007829|PDB:5BYZ"
FT   STRAND          313..316
FT                   /evidence="ECO:0007829|PDB:5BYY"
FT   HELIX           318..327
FT                   /evidence="ECO:0007829|PDB:5BYZ"
FT   HELIX           332..334
FT                   /evidence="ECO:0007829|PDB:5BYZ"
FT   HELIX           338..342
FT                   /evidence="ECO:0007829|PDB:5BYZ"
FT   HELIX           345..347
FT                   /evidence="ECO:0007829|PDB:5BYZ"
FT   TURN            348..350
FT                   /evidence="ECO:0007829|PDB:5BYZ"
FT   HELIX           353..355
FT                   /evidence="ECO:0007829|PDB:5BYZ"
FT   HELIX           366..369
FT                   /evidence="ECO:0007829|PDB:5BYZ"
FT   STRAND          370..372
FT                   /evidence="ECO:0007829|PDB:4IC7"
FT   HELIX           374..393
FT                   /evidence="ECO:0007829|PDB:5BYZ"
FT   STRAND          396..398
FT                   /evidence="ECO:0007829|PDB:4IC7"
SQ   SEQUENCE   816 AA;  88386 MW;  27729FE31658CE3B CRC64;
     MAEPLKEEDG EDGSAEPPGP VKAEPAHTAA SVAAKNLALL KARSFDVTFD VGDEYEIIET
     IGNGAYGVVS SARRRLTGQQ VAIKKIPNAF DVVTNAKRTL RELKILKHFK HDNIIAIKDI
     LRPTVPYGEF KSVYVVLDLM ESDLHQIIHS SQPLTLEHVR YFLYQLLRGL KYMHSAQVIH
     RDLKPSNLLV NENCELKIGD FGMARGLCTS PAEHQYFMTE YVATRWYRAP ELMLSLHEYT
     QAIDLWSVGC IFGEMLARRQ LFPGKNYVHQ LQLIMMVLGT PSPAVIQAVG AERVRAYIQS
     LPPRQPVPWE TVYPGADRQA LSLLGRMLRF EPSARISAAA ALRHPFLAKY HDPDDEPDCA
     PPFDFAFDRE ALTRERIKEA IVAEIEDFHA RREGIRQQIR FQPSLQPVAS EPGCPDVEMP
     SPWAPSGDCA MESPPPAPPP CPGPAPDTID LTLQPPPPVS EPAPPKKDGA ISDNTKAALK
     AALLKSLRSR LRDGPSAPLE APEPRKPVTA QERQREREEK RRRRQERAKE REKRRQERER
     KERGAGASGG PSTDPLAGLV LSDNDRSLLE RWTRMARPAA PALTSVPAPA PAPTPTPTPV
     QPTSPPPGPV AQPTGPQPQS AGSTSGPVPQ PACPPPGPAP HPTGPPGPIP VPAPPQIATS
     TSLLAAQSLV PPPGLPGSST PGVLPYFPPG LPPPDAGGAP QSSMSESPDV NLVTQQLSKS
     QVEDPLPPVF SGTPKGSGAG YGVGFDLEEF LNQSFDMGVA DGPQDGQADS ASLSASLLAD
     WLEGHGMNPA DIESLQREIQ MDSPMLLADL PDLQDP
//
